Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
36 hedge funds and large institutions have $6.42M invested in Unity Biotechnology in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 8 closing their positions.
9,278% more call options, than puts
Call options by funds: $3.75M | Put options by funds: $40K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.43% less ownership
Funds ownership: 18.75% → 18.32% (-0.43%)
7% less capital invested
Capital invested by funds: $6.87M → $6.42M (-$451K)
10% less funds holding
Funds holding: 40 → 36 (-4)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$103K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$50.8K |
| 3 |
Jane Street
New York
|
+$45.3K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$23.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$56.2K |
| 2 |
Two Sigma Investments
New York
|
-$54.8K |
| 3 |
VF
Virtu Financial
New York
|
-$46K |
| 4 |
Morgan Stanley
New York
|
-$41.8K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$33.6K |
UBX Hedge Fund Activity: Q3 2023 in Review
36 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q3 2023, worth a combined $6.42M — down 6.6% from $6.87M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of UBX and 4 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 6 added.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $103K. The largest seller was Dimensional Fund Advisors, cutting an estimated $56.2K.
- 36 institutional investors held Unity Biotechnology (UBX) as of Q3 2023, down from 40 in Q2 2023.
- Funds reported $6.42M of Unity Biotechnology stock for Q3 2023, down 6.6% quarter-over-quarter.
- 4 funds opened new Unity Biotechnology positions in Q3 2023 and 8 closed out, a net change of -4 holders.
- The largest Unity Biotechnology buyer in Q3 2023 was Alyeska Investment Group, an estimated $103K added.
- The largest Unity Biotechnology seller in Q3 2023 was Dimensional Fund Advisors, an estimated $56.2K sold.
Based on aggregated 13F filings for Q3 2023.